{"organizations": [], "uuid": "d2c405970848254d56bea891cc617ebe2f03c6ed", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.pharmamedtechbi.com", "main_image": "", "site_section": "http://feeds.feedburner.com/PharmaBiotechFinancing", "section_title": "Pharma/Biotech Financing From Elsevier Business Intelligence", "url": "https://www.pharmamedtechbi.com/deals/201530616?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d(%2540industries%253d%2522Pharmaceuticals%2522)%2520and%2520(%2540industries%253d%2522Biotechnology%2522)%2520and%2520(%2540dealtype%253d%2522Financing%2522)", "country": "IL", "title": "Cardiome nets $19mm via bought deal financing", "performance_score": 0, "site": "pharmamedtechbi.com", "participants_count": 0, "title_full": "Cardiome nets $19mm via bought deal financing", "spam_score": 0.0, "site_type": "news", "published": "2015-08-07T02:40:00.000+03:00", "replies_count": 0, "uuid": "d2c405970848254d56bea891cc617ebe2f03c6ed"}, "author": "", "url": "https://www.pharmamedtechbi.com/deals/201530616?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d(%2540industries%253d%2522Pharmaceuticals%2522)%2520and%2520(%2540industries%253d%2522Biotechnology%2522)%2520and%2520(%2540dealtype%253d%2522Financing%2522)", "ord_in_thread": 0, "title": "Cardiome nets $19mm via bought deal financing", "locations": [], "entities": {"persons": [], "locations": [], "organizations": []}, "highlightText": "", "language": "english", "persons": [], "text": "Cardiome nets $19mm via bought deal financing Deal Date: Jul-01-2015 / Deal # 201530616 Executive Summary \nCardiovascular-focused Cardiome Pharma Corp. netted $19mm through a bought deal financing of 2.5mm common shares at $8.00. The company originally planned to sell 1.9mm shares. Some of the funds will support ongoing Phase III development of IV and oral vernakalant for atrial fibrillation, and the pulmonary arterial hypertension therapy Trevyent , which was recently licensed from SteadyMed . Additional money will be put towards expanded marketing efforts for Brinavess , Aggrastat , and Esmocard .", "external_links": [], "published": "2015-08-07T02:40:00.000+03:00", "crawled": "2015-08-07T14:44:52.570+03:00", "highlightTitle": ""}